Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

Sander Kelderman; Ton N Schumacher; Pia Kvistborg

doi:10.1016/j.ccell.2015.06.012

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy

Cancer Cell. 2015 Jul 13;28(1):11-3. doi: 10.1016/j.ccell.2015.06.012.

Authors

Sander Kelderman¹, Ton N Schumacher¹, Pia Kvistborg²

Affiliations

¹ Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands.
² Division of Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address: p.kvistborg@nki.nl.

PMID: 26175412
DOI: 10.1016/j.ccell.2015.06.012

Abstract

Immune checkpoint-blocking therapies have yielded positive clinical data in a series of human malignancies. Recent work from Le and colleagues strongly supports the use of these therapies for mismatch repair-deficient tumors, independent of underlying tumor type. These data suggest the importance of sensing the consequences of DNA damage in cancer immunotherapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
DNA Mismatch Repair
Humans
Neoplasms / drug therapy*
Neoplasms / metabolism
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Tumor Microenvironment / drug effects

Substances

Antibodies, Monoclonal
Antineoplastic Agents
PDCD1 protein, human
Programmed Cell Death 1 Receptor